1-Jahres-Chart
5-Tage-Chart
| Realtime | Geld | Brief | Zeit |
|---|---|---|---|
| 0,817 | 0,967 | 14.05. |
- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| Di | Nanoform Finland Oyj: Inside information: Nanoform Signs First Exclusivity Agreement for Ultra-High Concentration Subcutaneous Delivery | 448 | GlobeNewswire (Europe) | Nanoform Finland Plc | Inside Information | May 12, 2026 at 08:00:00 EEST
Helsinki, Finland - Nanoform Finland Plc ("Nanoform"), the medicine performance-enhancing company, today announced that it has... ► Artikel lesen | |
| 21.04. | Nanoform Finland Oyj: Resolutions of Nanoform Finland Plc's Annual General Meeting on April 21, 2026 | 392 | GlobeNewswire (Europe) | Nanoform Finland Plc | Company Release | April 21, 2026 at 12:20:00 EEST
Nanoform Finland Plc (the "Company" or "Nanoform") held its Annual General Meeting for 2026 on April 21, 2026 at the Company's... ► Artikel lesen | |
| 02.03. | Nanoform Finland Oyj: The Board of Directors of Nanoform Finland Plc decided on issue of stock options under an option program open to all employees | 739 | GlobeNewswire (Europe) | Nanoform Finland Plc | Company Release | March 02, 2026 at 08:10:00 EET
Helsinki, Finland - The Annual General Meeting of Nanoform Finland Plc ("Nanoform") has on 15 April 2025 authorized the company's... ► Artikel lesen | |
| 26.02. | Nanoform Finland Oyj: Nanoform Q4 & FY2025 report - Next: the submission of a marketing authorization application for Nanoenzalutamide in Europe | 2.251 | GlobeNewswire (Europe) | Nanoform Finland Plc | Company Release | February 26, 2026 at 08:10:00 EET
Product kernel strategy continues to gain traction. Nanoenzalutamide: pivotal human fed and fasted study concluded, three more... ► Artikel lesen | |
| 07.01. | Nanoform Finland Oyj: Inside information: Nanoform starts change negotiations as part of announced new midterm business targets for 2030 | 978 | GlobeNewswire (Europe) | Nanoform Finland Plc | Inside Information | January 07, 2026 at 08:05:00 EET
Helsinki, Finland - Nanoform Finland Plc ("Nanoform") starts change negotiations in accordance with the Act on Cooperation.... ► Artikel lesen | |
| 16.12.25 | Nanoform Finland Oyj: Inside information: Nanoform announces new midterm business targets for 2030 | 1.424 | GlobeNewswire (Europe) | Nanoform Finland Plc | Inside Information | December 16, 2025 at 07:00:00 EET
Helsinki, Finland - Nanoform Finland Plc ("Nanoform"), the medicine performance-enhancing company, today announced new midterm... ► Artikel lesen | |
| 12.11.25 | Nanoform Finland Oyj: Nanoform Q3 report: Momentum in kernels continues, commercial cGMP manufacturing license received, first near-term target for 2026 set | 1.757 | GlobeNewswire (Europe) | Nanoform Finland Plc | Company Release | November 12, 2025 at 08:10:00 EET
Our product kernels see good momentum. Nanoenzalutamide progresses with the fed arm of the pivotal human study. Licensing and... ► Artikel lesen | |
| 11.11.25 | Nanoform Finland Oyj: Inside information made public: Nanoform Granted European Commercial cGMP Manufacturing License | 721 | GlobeNewswire (Europe) | Nanoform Finland Plc | Inside Information | November 11, 2025 at 08:00:00 EET
Helsinki, Finland - Nanoform Finland Plc ("Nanoform"), the medicine performance-enhancing company, today announced that... ► Artikel lesen | |
| NANOFORM FINLAND Aktie jetzt für 0€ handeln | |||||
| 27.10.25 | Nanoform Finland Oyj: Nanoform Partners With Revio Therapeutics To Develop Long-Acting Locally-Delivered Hydrogel Nanoformulation To Treat Glioma | 879 | GlobeNewswire (Europe) | Nanoform Finland Plc | Press Release | October 27, 2025 at 09:10:00 EET
Helsinki, Finland - Nanoform Finland Plc ("Nanoform"), the medicine performance-enhancing company, today announced a partnership... ► Artikel lesen | |
| 14.10.25 | Nanoform Finland Oyj: Nanoform Outlicenses Nanoencorafenib And Signs Development And Commercialisation Agreement With A.forall And IMGA | 924 | GlobeNewswire (Europe) | Nanoform Finland Plc | Press Release | October 14, 2025 at 09:30:00 EEST
Helsinki, Finland - Nanoform Finland Plc ("Nanoform"), the medicine performance-enhancing company, today announced that it has... ► Artikel lesen | |
| 30.09.25 | Nanoform Finland Oyj: Nanoform Expands Commercial Presence In Asia With A&ls Pharma In South Korea | 915 | GlobeNewswire (Europe) | Nanoform Finland Plc | Press Release | September 30, 2025 at 09:30:00 EEST
Helsinki, Finland - Nanoform Finland Plc ("Nanoform"), the medicine performance-enhancing company, today announced it has entered... ► Artikel lesen | |
| 21.08.25 | Nanoform Finland Oyj: Nanoform Q2 2025 report: Continued progress on many fronts, supportive first preliminary pivotal nanoenzalutamide study results | 1.767 | GlobeNewswire (Europe) | Nanoform Finland Plc | Company Release | August 21, 2025 at 08:10:00 EEST
First preliminary pivotal study results supportive for project Nanoenzalutamide to continue to progress towards the markets.... ► Artikel lesen | |
| 12.06.25 | Nanoform Finland Oyj: Nanoform starts Pivotal Human Bioequivalence Studies of Nanoenzalutamide | 1.257 | GlobeNewswire (Europe) | Nanoform Finland Plc | Press Release | June 12, 2025 at 08:10:00 EEST
HELSINKI, FINLAND, June 12, 2025 - Nanoform Finland Plc, the medicine performance-enhancing company, today announced that it had... ► Artikel lesen | |
| 20.05.25 | Nanoform Finland Oyj: Nanoform Q1 2025 report: Deal mosaic emerge and commercial value clearly seen in our CESS technology | 1.629 | GlobeNewswire (Europe) | Nanoform Finland Plc | Company Release | May 20, 2025 at 08:10:00 EEST
Term sheets agreed for several key markets around nanoenzalutamide1). First term sheet also signed around nanoencorafenib2). Negotiations... ► Artikel lesen |
14 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| FORMYCON | 19,000 | -0,84 % | Formycon zieht durch: Steht hier der Beginn einer neuen Rally? - Verpassen Sie das nicht | ||
| ONTO INNOVATION | 237,40 | +0,34 % | Why Onto Innovation (ONTO) Might be Well Poised for a Surge | ||
| KOPIN | 4,723 | +10,51 % | Stifel raises Kopin stock price target on diverse award wins | ||
| RIBER | 13,580 | +7,27 % | Riber: Margen steigen, KI-Boom treibt - Hidden Champion vor nächsten Kursschub? | Hightech "Made in France" mit Rückenwind durch KI und Photoniks: Riber verbessert trotz leicht rückläufigem Umsatz deutlich seine Profitabilität und könnte vor einem neuen Wachstumszyklus stehen. Riber... ► Artikel lesen | |
| GAUZY | 0,890 | +13,38 % | GAUZY LTD: Gauzy Announces Receipt of Nasdaq Notification Regarding Minimum Bid Price Deficiency | TEL AVIV, Israel, March 20, 2026 (GLOBE NEWSWIRE) -- Gauzy Ltd. (Nasdaq: GAUZ) ("Gauzy" or the "Company"), a global leader in vision and light control technologies, today announced that on March 17... ► Artikel lesen | |
| SMOLTEK NANOTECH | 0,214 | +1,90 % | Communiqué from the 2026 Annual General Meeting of Smoltek Nanotech Holding AB (publ) | ||
| ZENTEK | 0,850 | -0,58 % | Zentek Ltd.: Zentek's ZenGUARD Enhanced Air Filters Now Available for Direct Procurement by All Federal Departments and Agencies | Guelph, Ontario--(Newsfile Corp. - May 13, 2026) - Zentek Ltd. (TSXV: ZEN) (NASDAQ: ZTEK) ("Zentek" or the "Company") is pleased to announce that Innovative Solutions Canada ("ISC") has added ZenGUARD... ► Artikel lesen | |
| OBDUCAT | 0,045 | -0,44 % | XFRA CAPITAL ADJUSTMENT INFORMATION - 31.12.2025 | Das Instrument OMAX SE0000722365 VIVESTO AB SK-,10 EQUITY wird cum Kapitalmassnahme gehandelt am 31.12.2025 und ex Kapitalmassnahme am 02.01.2026 The instrument OMAX SE0000722365 VIVESTO AB SK-,10 EQUITY... ► Artikel lesen | |
| DOTZ NANO | 0,024 | -5,58 % | XFRA 57N: WIEDERAUFNAHME/RESUMPTION | FOLGENDE(S) INSTRUMENT(E) WIRD/ WERDEN WIEDER IN DEN HANDEL AUFGENOMMEN MIT FOLGENDEM TRADING SCHEDULE.THE FOLLOWING INSTRUMENT(S) IS/ARE RESUMED TRADING WITH FOLLOWING TRADING SCHEDULE:INSTRUMENT NAME... ► Artikel lesen | |
| GOMSPACE | 1,674 | +3,08 % | GomSpace A/S: GomSpace reports a solid Q1 with 43% revenue growth and positive EBITDA | GomSpace continues to demonstrate strong revenue growth, delivers positive EBITDA, and takes first step toward delivering sovereign satellite communication solutions in Ukraine.STOCKHOLM... ► Artikel lesen | |
| ACACIA RESEARCH | 3,980 | 0,00 % | Acacia Research Q1 2026 slides show mixed results, strong liquidity | ||
| SOLESENCE | 1,320 | 0,00 % | SOLESENCE, INC. - 10-Q, Quarterly Report | ||
| NANOVIRICIDES | 1,440 | -1,37 % | Recent Hantavirus On A Cruise Ship Highlights the Need for Broad-Spectrum Antiviral Drugs Such as NV-387, Says NanoViricides | SHELTON, CT / ACCESS Newswire / May 11, 2026 / NanoViricides, Inc. (NYSE American:NNVC) (the "Company"), a clinical stage leader developing antiviral drugs that viruses cannot escape, emphasizes the... ► Artikel lesen | |
| NVE | 78,50 | -4,27 % | Morning Market Movers: Click Holdings, Everspin Technologies, NVE Corporation, Beazer Homes USA See Big Swings | CANBERA (dpa-AFX) - At 8:20 a.m. ET on Monday, premarket trading is seeing notable activity in several stocks, with early price movements signaling potential opportunities before the opening... ► Artikel lesen | |
| ADVANCE ZINCTEK | 0,390 | -0,51 % | ADVANCE ZINCTEK LIMITED: Change of Director's Interest Notice - Lev Mizikovsky |
Das Unternehmen NANOFORM FINLAND OYJ kann der Branche Nanotechnologie zugeordnet werden. Die relative Kursveränderung beträgt aktuell -0,32 % bei einem Aktienkurs von 0,949 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu NANOFORM FINLAND OYJ finden Sie auf Wallstreet Online.